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Posterior cortical atrophy (PCA) is an uncommon ear-
ly-onset dementia characterized by progressive visuospa-
tial dysfunction  [1–3] . Elements of Balint’s syndrome, 
Gerstmann’s syndrome, visual agnosia and topographi-
cal disorientation are typical manifestations of PCA. 
Memory and insight remain relatively intact. Alzheimer’s 
amyloid plaques and neurofibrillary tangles in posterior 
brain regions are the most common underlying pathol-
ogy, indicating that PCA most often represents a focal, 
mostly presenile variant of Alzheimer’s disease (AD)  [4–
6] . One of the most sensitive and specific approaches to 
predict AD in vivo is the analysis of A  1–42 , T-tau and P-
tau in the cerebrospinal fluid (CSF). When combined, the 
sensitivity and specificity for the diagnosis of AD have 
been found to be between 80 and 90%  [6] . Analysis of 
these biomarkers may be helpful in predicting Alzhei-
mer’s pathology also in PCA. In this study, we postulated 
that an AD-typical CSF protein profile consisting of low 
A  1–42 and high T-tau and P-tau 181 concentrations would 
also be observed in PCA patients.
 Methods 
 Selection of Cases 
 We identified 12 patients with PCA who were evaluated at the 
Center for Geriatric Medicine and Gerontology, University Hos-
pital Freiburg, Germany, and the Memory Clinic of the Univer-
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 Abstract 
 Objective: Our purpose was to measure A  1–42 , T-tau and
P-tau 181 in the cerebrospinal fluid (CSF) of patients with pos-
terior cortical atrophy (PCA), a presenile dementia likely to 
represent a variant of Alzheimer’s disease (AD).  Methods: 
CSF samples from 34 subjects including 9 patients with PCA, 
11 age-matched patients with AD and 14 age-matched cog-
nitively healthy controls were analyzed using commercially 
available ELISA kits.  Results: The A  1–42 , T-tau and P-tau 181 
levels in PCA patients differed significantly (p  ! 0.02) from 
those in healthy controls but were indistinguishable from 
subjects with a clinical diagnosis of AD.  Conclusion: High T-
tau and P-tau 181 and low A  1–42 levels in PCA – typically ob-
served in AD – indicate that the underlying pathology of PCA 
is usually AD. If these findings are replicated in PCA patients 
with autopsy-confirmed AD neuropathology, PCA patients 
may be eligible for disease-modifying AD treatments. 
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sity Hospital Basel, Switzerland, between 2005 and 2007. Inclu-
sion criteria for PCA were applied according to proposed clinical 
criteria  [2] . Required are all of the following: (1) insidious onset 
and gradual progression; (2) presentation with visual complaints 
despite intact primary visual functions; (3) evidence of predomi-
nant complex visual disorder on examination; (4) proportionally 
less impaired memory and verbal fluency, and (5) relatively pre-
served insight with or without depression. It was possible to col-
lect CSF in 9 of these 12 patients with PCA. The clinical features 
of these 9 patients are summarized in  table 1 . All subjects and 
their next of kin gave written informed consent for research par-
ticipation. The study was approved by the local ethics committee.
 Selection of Controls 
 Fourteen cognitively healthy individuals from a longitudinal 
ageing study were matched with the PCA group according to age, 
gender and education. Eleven early-onset AD patients served as 
disease controls. These AD cases were sporadic, i.e. there was no 
evidence of an autosomal-dominant mode of inheritance in any 
patient. All subjects underwent detailed neurological and neuro-
psychological examination, brain imaging (MRI or CT, CBF-
SPECT in selected cases), and routine blood tests.
 CSF Analysis 
 From each subject 14 ml of CSF were collected in polypropyl-
ene tubes, transferred on ice and stored at –80   °   C within 1 h. 
 A  1–42 , T-tau and P-tau 181 were measured in duplicates unknown 
to the analyst using a commercial sandwich ELISA kit (Innoge-
netics  , Belgium).
 Statistics 
 The statistical analysis was done with SPSS for Windows (SPSS 
Inc., Chicago, Ill., USA). To test for differences between the groups 
we used the Mann-Whitney U and Kruskal-Wallis tests, since the 
assumptions of normality were not met. Gender and APOE 4 dif-
ferences between the groups were analyzed with the   2 test.
Table 2.  Basic characteristics of the 34 subjects
PCA (n = 9) AD (n = 11) HC (n = 14) p value
Age at disease onset, years 56.7 (7.6) 58.3 (5.1) n.a. 0.38
Age at lumbar puncture, years 60.9 (7.7) 61.6 (6.2) 62.6 (5.1) 0.81
Sex (m/f) 4/5 4/7 7/7 0.79
Education, years 11.5 (2.3) 12.0 (2.0) 13.5 (2.8) 0.25
Disease duration, years 4.2 (2.6) 3.4 (2.5) n.a. 0.49
APOE 4 allele, % 38.9 50.0 14.3 0.48, PCA vs. AD
MMSE score at time of lumbar puncture 17.7 (6.2) 23.6 (3.3) 29.1 (1.2) 0.02, PCA vs. AD
F igures are means with standard deviations in parentheses.
MMSE = Mini-Mental State Examination (0–30).
Table 1.  Clinical characteristics of the  patients with PCA (n = 9)
1 2 3 4 5 6 7 8 9
Elements of Balint’s syndrome + + + + + + + + +
Elements of Gerstmann’s syndrome + + + + + + + + +
Dressing apraxia – (+) + – + (+) + – –
Environmental disorientation – – + + + + – – –
Pure alexia – – + – – – + – –
Ideomotor apraxia – (+) – + + + + + +
Constructive apraxia + + + + + + + + +
Prosopagnosia – – (+) – + – – – +
Apperceptive agnosia – + + + + – + – +
Visual field deficit – + + + – – – (+) –
Achromatopsia or color agnosia – – – + – – + – –
Extrapyramidal motor signs – – – – – – – (+) (+)
+ = Present; – = absent; (+) = possible.
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 Results 
 Mean age at disease onset and disease duration were 
similar in PCA and AD (56.7 vs. 58.3 years, p = 0.38, and 
4.2 vs. 3.4 years, p = 0.49). The MMSE score was lower in 
PCA compared with AD (mean = 17.7 vs. 23.6, p = 0.02; 
 table 2 ). CSF data are shown in  figure 1 . PCA and AD had 
lower A  1–42 levels compared with healthy controls (HC; 
median = 424 and 424 pg/ml vs. 845 pg/ml; p = 0.0004 
and p = 0.0005). The T-tau values were higher in PCA and 
AD compared to HC (median = 528 and 557 pg/ml vs. 251 
pg/ml; p = 0.0001 and p = 0.0002). The P-tau 181 concen-
trations were higher in PCA and AD compared with HC 
(median = 70 and 78 pg/ml vs. 47 pg/ml; p = 0.0015 and 
p = 0.0196). No differences were found between PCA and 
AD for A  1–42 (p = 0.6759), T-tau (p = 0.4941) and P-tau 181 
(p = 0.3817).
 Discussion 
 Our results indicate that CSF A  1–42 , T-tau and P-
tau 181 findings characteristic of AD are also observed in 
PCA. In all 9 PCA patients at least 1 of these 3 markers 
was outside the published normal range  [7] . To the best of 
our knowledge, this is the first study to report detailed 
CSF protein findings in a group of PCA patients and to 
provide another line of evidence for a close pathophysi-
ological link between PCA and AD. Recently, low A  1–42 
and high CSF P-tau 199 values were reported in a patient 
with PCA  [8] using the same ELISA test as in this study. 
However, as in another PCA case report  [9] , no interpre-
tation of the findings was given. Predicting the underly-
ing Alzheimer pathology in focal atrophy syndromes 
such as PCA is of high clinical interest as soon as disease-
modifying treatments for AD become available. In 2 re-
cent PCA case studies, increased uptake of C11-labeled 
Pittsburgh Compound B in the occipital cortex indicated 
that imaging of fibrillary amyloid in PCA is feasible in 
vivo  [6, 9] . However, the costs of amyloid PET scans are 
high, and their availability is limited. In contrast, CSF 
analysis is inexpensive and well tolerated in the elderly 
 [11] . A combination of CSF A  1–42 , T-tau and P-tau 181 has 
been shown to be sensitive and specific for the diagnosis 
of AD  [6] . CSF protein analysis may therefore be more 
suitable for detecting AD-specific protein abnormalities 
with atypical presentation of AD such as PCA, progres-
sive mixed aphasia, progressive nonfluent aphasia or cor-
ticobasal syndrome. A recent autopsy study suggested 
that plaques and tangles are the underlying pathology in 
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 Fig. 1. A  1–42 , T-tau, and P-tau 181 concentrations in CSF (medians 
and interquartile ranges). 
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a substantial number of these patients (46–100%)  [4] . In 
a study on focal cerebral atrophies, all 7 subjects with 
PCA showed Alzheimer pathology at autopsy and none 
had alternative published histopathology such as cortico-
basal degeneration, Creutzfeldt-Jakob disease, dementia 
with Lewy bodies or progressive subcortical gliosis  [5, 
12] . Should our CSF results be confirmed in a larger co-
hort of PCA patients with autopsy-confirmed amyloid 
plaques and tau aggregates in posterior brain regions, pa-
tients with PCA syndrome and AD-typical CSF findings 
may be candidates for AD trials targeting at the modifi-
cation of A  1–42 or tau protein. The limitations of this 
study include the small number of PCA cases and the 
probability of a more advanced disease stage in the PCA 
group compared to the AD group. The disease duration 
was longer and the MMSE scores were significantly lower 
in the PCA group. However, data from the literature in-
dicate that alterations in tau and A  1–42 occur early in the 
disease course and do not (A  1–42 ) or only slightly (T-tau) 
change over time  [13] . Moreover, we found no correla-
tions between the CSF biomarkers (tau, P-tau 181 , A  1–42 ) 
and the MMSE scores either in the PCA group, in the AD 
group or in the combined group (AD and PCA). It is 
therefore unlikely that higher MMSE scores in the PCA 
group would have altered the interpretation of our data.
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